Canada’s health minister calls for action to fight the worrisome tide of opioid addiction and opioid-related deaths in Canada. Delivra is a Canadian-born pain relief solution that is taking to the front lines in this fight with non-addictive cannabis-based product lines.

Burlington, Ontario, December 7, 2016 – Responding to Canada’s opioid crisis, Delivra announced significant milestones over the past year which deliver opioid-free pain relief to Canadians. Delivra is a biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. 

Earlier this year, Delivra demonstrated the ability to deliver celecoxib (CelebrexTM) to provide sustained pain reduction, as its multi-layer liposomal system gradually releasing the medicine to the area of need.  As such, topical Delivra-celecoxib (CelebrexTM) cream offers significant advantages to oral medication with better localization of the drug at the site of interest for quicker relief, longer lasting and using less drug.

Delivra is also finding success in Canada’s legal medical marijuana industry. This year Delivra has signed agreements with both Canopy Growth and Kalytera Therapeutics to bring cannabis and endocannabinoid-like treatments to market using innovative transdermal technologies.

“Cannabinoid therapy is a rapidly emerging field of medicine, quickly demonstrating its applicability to a range of acute and chronic indications, in particular, those related to pain management,” said Dr. Joseph Gabriele, founder and CEO of Delivra.

Many oral medications degrade during passage through the gastrointestinal tract. Delivra is helping to deliver beneficial cannabinoid compounds through the skin directly to affected areas.

ABOUT DELIVRA CORP.

Delivra Corp. (“Delivra” or the “Company”) is a biotechnology company that has a proprietary transdermal delivery system that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. In parallel with its consumer products business, Delivra has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for the United States.

For more information, please contact:

Investor Relations:

Nicole Marchand

416-428-3533

ir@delivrainc.com